This Medudy course is a video tutorial for physicians on the topic of "Atezolizumab plus Bevacizumab in cervical cancer". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
In the earlier GOG240 study, bevacizumab together with chemotherapy was established as the standard first-line treatment for metastatic or recurrent cervical cancer. In today's study - also known as the BEATcc study - the authors investigated the addition of an immune checkpoint inhibitor to this standard therapy.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
